Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced its upcoming Annual General Meeting scheduled for May 28, 2025. The meeting will address several key resolutions, including the approval of the 2024 work reports, financial reports, and profit distribution plan. Additionally, the company will consider the appointment and re-election of various directors and supervisors, as well as the re-appointment of Deloitte Touche Tohmatsu as the auditor for 2025. A special resolution will also be discussed regarding the granting of a general mandate to the Board for issuing new shares.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative cancer immunotherapy products. The company is based in Shanghai, China, and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: 26.36%
Average Trading Volume: 6,562,729
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.98B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.